Optimizing Administration of Epidermal Growth Factor Receptor–Targeted Agents in the Treatment of Colorectal Cancer

摘要: Abstract The monoclonal antibodies against the epidermal growth factor receptor (EGFR) are active in patients with metastatic colorectal cancer (CRC; mCRC). This activity has been shown initially irinotecan-and chemotherapy-refractory mCRC. correlation of rash after EGFR inhibitors and led to concept dose until study. Clinical trials evaluating this ongoing. However, many unresolved challenges remain regarding question. New include development most optimal schedule evaluation their role less advanced stages preoperative treatment liver metastases CRC.